The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mitochondrial-targeted and ROS-responsive nanocarrier via nose-to-brain pathway for ischemic stroke treatment
Open accessAbstract
Oxidative stress injury and mitochondrial dysfunction are major obstacles to neurological functional recovery after ischemic stroke. The development of new approaches to simultaneously diminish oxidative stress and resist mitochondrial dysfunction is urgently needed. Inspired by the overproduced reactive oxygen species (ROS) at ischemic neuron mitochondria, multifunctional nanoparticles with ROS-responsiveness and mitochondrial-targeted (SPNPs) were engineered, achieving specific targeting delivery and controllable drug release at ischemic penumbra. Due to the nose-to-brain pathway, SPNPs which were encapsulated in a thermo-sensitive gel by intranasal administration were directly delivered to the ischemic penumbra bypassing the blood‒brain barrier (BBB) and enhancing delivery efficiency. The potential of SPNPs for ischemic stroke treatment was systematically evaluated in vitro and in rat models of middle cerebral artery occlusion (MCAO). Results demonstrated the mitochondrial-targeted and protective effects of SPNPs on H2O2-induced oxidative damage in SH-SY5Y cells. In vivo distribution analyzed by fluorescence imaging proved the rapid and enhanced active targeting of SPNPs to the ischemic area in MCAO rats. SPNPs by intranasal administration exhibited superior therapeutic efficacy by alleviating oxidative stress, diminishing inflammation, repairing mitochondrial function, and decreasing apoptosis. This strategy provided a multifunctional delivery system for the effective treatment of ischemic injury, which also implies a potential application prospect for other central nervous diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · cited 1×
“As a central player in the regulation of apoptosis, the BCL-2 protein family could regulate apoptosis by the control of mitochondrial permeability 4,38,39 .”
BackgroundAdvances and challenges in stroke rehabilitation
Stinear, C. M., Lang, C. E., Zeiler, S., & Byblow, W. D. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30415-6 · Cited by 792 · cited 2×
“This narrow therapeutic window increases the treated difficulty, and less than 10% of patients could be treated in time 1,5 .”
BackgroundInfluential
Cited by
Bioactive Ceria Nanoenzymes Target Mitochondria in Reperfusion Injury to Treat Ischemic Stroke
Liao, J., Li, Y., Fan, L., Sun, Y., Gu, Z., Xu, Q.-Q., Wang, Y., Xiong, L., Xiao, K., Chen, Z.-S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c10982 · Cited by 104
Complex bioactive nanofibrous dura mater repairs traumatic brain injury
Chen, S., Zhang, X., Guo, Q., Yan, Y., Fu, M., Wang, Y., & Wu, T. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00621 · Cited by 3
Metadata
- Authors
- Zhang, Y., Zhang, H., Zhao, F., Jiang, Z., Cui, Y., Ou, M., Mei, L., & Wang, Q.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2023-12
- Volume
- 13
- Issue
- 12
- Pages
- 5107-5120
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W4381335724
- Cited by
- 160
- References
- 2
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitochondrial-targeted and ROS-responsive nanocarrier via nose-to-brain pathway for ischemic stroke treatment. https://app.cochat.ai/papers/10.1016/j.apsb.2023.06.011
- The paper
- Zhang, Y., Zhang, H., Zhao, F., Jiang, Z., Cui, Y., Ou, M., Mei, L., & Wang, Q. (2023). Mitochondrial-targeted and ROS-responsive nanocarrier via nose-to-brain pathway for ischemic stroke treatment. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2023.06.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.